Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/630,239	SANGHVI ET AL.
	Examiner	Art Unit
	Humera N. Sheikh	1615
All Participants: Status of Application: <u>Allowed</u>		
(1) <u>Humera N. Sheikh</u> .	(3)	
(2) <u>Andrej Barbic, Ph.D.</u> .	(4)	
Date of Interview: 5 July 2006	Time: <u>1 pm (est)</u>	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative) Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:		
Part I.		
Rejection(s) discussed:		
Claims discussed: pending 1-23		
Prior art documents discussed: none		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: See Continuation Sheet		
Part III.		
 ☑ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above. 		
Junera Moule		
(Examiner)SPE Signature) (Applicant/	Applicant's Representative Si	gnature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

Examiner proposed the following claim amendments, which would place the application in condition for allowance: (1) To incorporate the recitation of a Markush grouping for the pharmaceutical 'diluent' in each of independent claims 1, 13 and 21; (2) To incorporate a Markush grouping for each of the hydrophilic compound, cross-linking agent and diluent for claim 21; (3) To recite or define 'sustained-release' in all generic claims, according to the definition in the instant specification on page 12. Examiner indicated that the recitation of all 3 components (hydrophilic compound, cross-linking agent & diluent) were needed to be defined in each of the independent claims in order to overcome any 112-1st written description issues. Examiner indicated that such claim amendments would render the case allowable. Applicant agreed to the changes suggested by the Examiner. Examiner will conduct an Examiner's Amendment making the necessary changes, upon attorney approval. Additionally, Applicant's representative informed Examiner regarding changes to claims 17 and 18. Specifically, in claim 17, the ratio 1:01 should be changed to 1:0.1. Also, in claim 18, the ratio 1:03 should read as 1:0.3 instead. A Notice of Allowability will be issued in due course.